Abeona Therapeutics Inc vs Huntington Ingalls Industries Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Huntington Ingalls Industries Inc trades at $326.59 (market cap $12.92B). The key difference: Huntington Ingalls Industries Inc is far larger — about 30.7× Abeona Therapeutics Inc's market cap, and Huntington Ingalls Industries Inc pays a 1.68% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HII | |
|---|---|---|
Market Cap | $421.19M | $12.92B |
Sector | Health | Technology |
52-Week High | $7.45 | $453.73 |
52-Week Low | $4.17 | $265.40 |
Enterprise Value | $276.10M | $15.84B |
Dividend Yield | — | 1.68% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
HII trades at $326.80, down 1.21% over the past day, with a bullish technical outlook supported by moving averages and key support at $326. The company reported strong Q2 2026 earnings of $5.27 EPS, beating estimates, with revenue growth of 10.9% year-over-year. Recent contract awards, including a $2.2 billion task order for surveillance and intelligence capabilities, highlight ongoing government demand. Valuation metrics show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.
The investment outlook is positive, driven by robust defense contracts and operational improvements, with a consensus price target of $359.67 suggesting 10% upside. Risks include dependence on U.S. military spending and potential political headwinds affecting naval budgets. Analyst sentiment is mixed but leans bullish, with 44% buy ratings. Overall, HII presents a solid opportunity in the defense sector, though investors should monitor contract execution and macroeconomic factors.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →